RAP are doing clinical trials for COPD management aren't they (similar to that technology)? Given ResAppDx already detect acute respiratory disease for COPD, I don't see it as an issue.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint